Meritxell Teixidó: “Many drugs do not reach the brain, and Gate2Brain’s technology helps to overcome this bottleneck”

At the Bosch i Gimpera Foundation we connect university
and business to transfer innovation to society

What we do

Contract Research

We provide customized research services for companies

Business Creation

We promote innovative new companies

Technologies, materials, and licences

We commercialize the technologies developed by researchers to make them available to companies

Who can benefit from our services

Researchers

We help you so that your research has an impact on society

Companies

We propose to improve the competitiveness of your business through innovation

Investors and mentors

We provide you with opportunities as an investor, business angel, or mentor

Results

670

companies and institutions innovate with us

24.31M€

for the UB in contracted revenue

1,921

active projects

The FBG in Figures >

Success Stories

An app to identify crop disorders and recommend potential treatments in the Middle East and North Africa

The application has been created by the Crop Ecophysiology team from the University of Barcelona and researchers from the International Center for Biosaline Agriculture (ICBA) in Dubai

SARS-CoV-2 wastewater surveillance

The UB Enteric Virus Group coordinates and tracks SARS-CoV-2 in wastewater in Spain and Catalonia

A test based on UB technology that enables tailor-made treatments for breast cancer

More Success Stories >

News

UB researchers awarded AGAUR-LLAVOR grant to develop artificial intelligence tool to detect infants at risk of neurodevelopmental delay

The University of Barcelona, through its technology and innovation transfer office the Bosch i Gimpera Foundation, has been awarded a...

UB researchers awarded AGAUR-LLAVOR grant to design new compounds to fight resistance to colorectal cancer treatments

The University of Barcelona, through its technology and innovation transfer office the Bosch i Gimpera Foundation, has been awarded a...

UB researchers awarded AGAUR-LLAVOR grant to design new drug targeting Alzheimer’s epigenetic target

Alzheimer’s is the most common cause of dementia and affects over 800,000 people in Spain. The University of Barcelona, through...

More news >

Utilitzem cookies de tercers amb finalitats tècniques i analítiques. Si continua navegant vol dir que accepta la nostra política de cookies. Més informació,plugin cookies política de cookies.

ACEPTAR
Aviso de cookies